Close to 130 industry and non-industry players, across the globe, claim to have the necessary expertise. <Roots Analysis>

The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise. Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process. Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers.

 

Key Inclusions

• A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
• An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
• Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.

To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this - https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

 

The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments:

• Target Disease Indication
• Breast Cancer
• Chronic Lymphocytic Leukemia
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Lupus Nephritis
• Melanoma
• Multiple Myeloma
• Primary Sjögren's Syndrome
• Others

 

• Target Immune Checkpoint
• B7-H3
• CD38
• CD40
• CD47
• Others

 

• Mechanism of Action
• Inhibitory
• Stimulatory

 

• Therapeutic Modality
• Monoclonal Antibody
• Small Molecule

 

• Type of Therapy
• Monotherapy
• Combination Therapy

 

• Route of Administration
• Intravenous
• Subcutaneous
• Others

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific and the Rest of the World

 

The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:

• Advanced Accelerator Applications
• Belgian Nuclear Research Center (SCK•CEN)
• Cardinal Health
• China Isotope & Radiation Corporation
• Curium Pharma
• DuChemBio
• Eckert & Ziegler
• Eczacibasi-Monrol
• GE Healthcare
• Jubilant DraxImage
• Lantheus Medical Imaging
• Nihon Medi-Physics
• Nordion
• PETNET Solutions
• SinoTau Pharmaceuticals
• SOFIE

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape
 

5. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Current Market Landscape
 

6. Nuclear Medicine and Radiopharmaceuticals Manufacturers in North America
 

7. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Europe
 

8. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Asia-Pacific And Rest of The World
 

9. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Company Competitiveness Analysis
 

10. Partnerships and Collaborations
 

11. Production and Supply Chain of Medical Isotope Molybdenum-99 (Technetium-99m)
 

12. Market Forecast and Opportunity Analysis
 

13. Concluding Remarks

 

14. Executive Insights

 

15. Appendix 1: Tabulated Data

 

16. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]